Navigation Links
The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Date:8/19/2007

Phase 2 Study to Explore the Efficacy of Novel Proteasome Inhibitor in

Patients with Relapsed and Refractory Multiple Myeloma

SOUTH SAN FRANCISCO, Calif. and NORWALK, Conn., Aug. 15 /PRNewswire/ -- The Multiple Myeloma Research Consortium (MMRC) and Proteolix, Inc. today announced the enrollment of the first patient in a multi-center Phase 2 clinical trial to study Proteolix's potent and selective proteasome inhibitor, carfilzomib (PR-171), in patients with relapsed and refractory multiple myeloma. Ten MMRC Member Institutions will participate in the study, under the MMRC leadership of Melissa Alsina, MD, H. Lee Moffitt Cancer Center & Research Institute. The nine additional sites are the City of Hope, Emory University, Cancer Center at Hackensack University Medical Center, Mayo Clinic, Princess Margaret/University Health Network, Saint Vincent's Comprehensive Cancer Center, University of Michigan, and Washington University.

The MMRC is the only research model of its kind that brings together 13 leading academic institutions to accelerate the development of novel and combination treatments for multiple myeloma, an incurable cancer of the plasma cell.

"Proteasome inhibitors are an important class of drugs for the treatment of multiple myeloma and we are proud to work with Proteolix to advance the clinical development of carfilzomib," said Kathy Giusti, Founder and Chief Executive Officer of the MMRC. "This trial and the others the MMRC are facilitating underscore our commitment to bring better, more effective treatments to myeloma patients as quickly as possible."

The trial will evaluate the overall response rate (ORR) for two cycles of carfilzomib in patients with multiple myeloma who have previously received specific FDA-approved therapies, have relapsed after two or more of such therapies, and are refractory to the most recently received therapy. Secondary objectives of this study include safety and tolerability, clinica
'/>"/>

SOURCE Proteolix

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... BERKELEY, Calif. , July 29, 2015 /PRNewswire/ ... of the Daiichi Sankyo Group, announced today that ... clinical trial results demonstrating that the investigational drug, PLX3397, ... in most patients with tenosynovial giant cell tumor (TGCT), ... tendon sheath. Following phase 1 dose-escalation, which ...
(Date:7/29/2015)... July 29, 2015  STAAR Surgical Company (NASDAQ: STAA ... and delivery systems for the eye today reported financial results ... Second Quarter Overview , Net Sales of $18.7 ... Unfavorable Currency Impact of $2.1 Million from the Weakening Euro ... and 13% in China , APAC Sales Down 1% ...
(Date:7/29/2015)... 2015  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ... second quarter ended June 30, 2015. "We ... and Fanapt" said Mihael H. Polymeropoulos M.D., Vanda,s President ... cycle management of our products set the stage for ... Financial Highlights , Total net product sales ...
Breaking Medicine Technology:Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 2Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 3Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 4Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 5STAAR Surgical Reports Second Quarter 2015 Results 2STAAR Surgical Reports Second Quarter 2015 Results 3STAAR Surgical Reports Second Quarter 2015 Results 4STAAR Surgical Reports Second Quarter 2015 Results 5STAAR Surgical Reports Second Quarter 2015 Results 6STAAR Surgical Reports Second Quarter 2015 Results 7STAAR Surgical Reports Second Quarter 2015 Results 8STAAR Surgical Reports Second Quarter 2015 Results 9STAAR Surgical Reports Second Quarter 2015 Results 10STAAR Surgical Reports Second Quarter 2015 Results 11STAAR Surgical Reports Second Quarter 2015 Results 12STAAR Surgical Reports Second Quarter 2015 Results 13STAAR Surgical Reports Second Quarter 2015 Results 14STAAR Surgical Reports Second Quarter 2015 Results 15STAAR Surgical Reports Second Quarter 2015 Results 16STAAR Surgical Reports Second Quarter 2015 Results 17STAAR Surgical Reports Second Quarter 2015 Results 18STAAR Surgical Reports Second Quarter 2015 Results 19STAAR Surgical Reports Second Quarter 2015 Results 20STAAR Surgical Reports Second Quarter 2015 Results 21STAAR Surgical Reports Second Quarter 2015 Results 22STAAR Surgical Reports Second Quarter 2015 Results 23STAAR Surgical Reports Second Quarter 2015 Results 24Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 2Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 3Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 4Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 5Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 6Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 7Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 8Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 9
(Date:7/30/2015)... ... July 30, 2015 , ... After a three year trial designed to study ... known as the “bionic eye,” researchers have determined the trial to be a success, ... facing or already affected by complete vision loss as a result of Retinitis pigmentosa. ...
(Date:7/30/2015)... ... 2015 , ... At the presentation of the 2015 Annual Meeting of the American Academy ... by the Journal of Arthroplasty pertaining to how soon after undergoing hip replacement surgery ... the study confirm what Santa Rosa Orthopaedics (SRO) surgeon Nathan Ehmer D.O ...
(Date:7/30/2015)... NY (PRWEB) , ... July 30, 2015 , ... ... the right and necessity for women to ensure their children have the nutrition ... of children from pre-birth by offering discount cards for many prescription pre-natal vitamins. ...
(Date:7/29/2015)... , ... July 30, 2015 , ... ... for their clients, BOC approved provider of online continuing education courses for ... offerings to their exclusive Andrews Research and Education Sports Medicine Series. , The ...
(Date:7/29/2015)... Mary, FL (PRWEB) , ... July 29, 2015 , ... ... Healthcare Providers and Systems (CAHPS) for PQRS Survey. , The CAHPS for PQRS ... In 2015, practices of 100 or more eligible providers must participate or they will ...
Breaking Medicine News(10 mins):Health News:The Vision Enhancing “Bionic Eye” Deemed Safe For Long Term Use After Three Year Clinical Trial 2Health News:SRO Surgeon Dr. Nathan Ehmer Backs Up Latest Study That Total Hip Replacement Surgery Patients Are Resuming Normal Activities Sooner 2Health News:SRO Surgeon Dr. Nathan Ehmer Backs Up Latest Study That Total Hip Replacement Surgery Patients Are Resuming Normal Activities Sooner 3Health News:Medicationdiscountcard.com Encourages Pre-Natal Wellness in Time for World Breast-Feeding Week 2Health News:Medicationdiscountcard.com Encourages Pre-Natal Wellness in Time for World Breast-Feeding Week 3Health News:Medicationdiscountcard.com Encourages Pre-Natal Wellness in Time for World Breast-Feeding Week 4Health News:Elite Online Continuing Education Provider Adds Six New Athletic Training Courses to Exclusive Andrews Research and Education Sports Medicine Series 2Health News:Elite Online Continuing Education Provider Adds Six New Athletic Training Courses to Exclusive Andrews Research and Education Sports Medicine Series 3Health News:Avatar Solutions Approved to Administer CAHPS for Physician Quality Reporting System (PQRS) 2Health News:Avatar Solutions Approved to Administer CAHPS for Physician Quality Reporting System (PQRS) 3
... in Bangladesh and other parts of Asia have been poisoned ... leached naturally from sediments, and now being tapped by shallow ... wells have been sunk 500 feet or more to purer ... out, contaminated water might filter down to replace it. Now, ...
... 11 October 2011 Alzheimer,s disease (AD) is a ... world. A new supplement to the Journal ... shows that multiple imaging systems are now available to ... "Alzheimer,s disease is now seen as a continuum ...
... is some evidence about the potential value of cognitive rehabilitation ... it is not sufficient to develop definitive guidelines on how ... CRT will work best for a particular patient, says a ... Research has yielded promising data on the effectiveness of some ...
... According to a study published in the October issue of ... phyllodes tumors rare breast malignancies accounting for 0.5 to ... more prevalent in Hispanic patients. Population-based estimates indicate that the ... women, with the highest frequencies in Hispanic women. Previous ...
... Lung cancer patients could receive safer and more efficient ... the University of Strathclyde in Glasgow. The scientists ... to patients through a nebuliser, rather than the current ... the treatment far more quickly than existing methods and ...
... ingredient ticagrelor can be prescribed in Germany in addition ... patients with acute ischaemia of the cardiac muscle. The ... (IQWiG) has now examined whether ticagrelor offers advantages to ... conventional drugs. This is the first co-called "early benefit ...
Cached Medicine News:Health News:Natural processes can limit spread of arsenic in water, says study 2Health News:Advances in brain imaging can expedite research and diagnosis in Alzheimer's disease 2Health News:Advances in brain imaging can expedite research and diagnosis in Alzheimer's disease 3Health News:Evidence points to potential roles for cognitive rehabilitation therapy in treating traumatic brain injury, but further research needed 2Health News:Evidence points to potential roles for cognitive rehabilitation therapy in treating traumatic brain injury, but further research needed 3Health News:Hispanic women have higher incidence of rare breast tumor 2Health News:Inhaler treatment for lung cancer 2Health News:Ticagrelor: Considerable added benefit for specific patients 2Health News:Ticagrelor: Considerable added benefit for specific patients 3Health News:Ticagrelor: Considerable added benefit for specific patients 4
Myoglobin RIA Lipid / Protein Quantification, Cardiovascular 024-IDC-11 Muscle Disease...
ACTH EIA Hypertension / Cardiac Evaluation, Cardiovascular 021-SDX018...
Anti-Gliadin IgG (Ab) EIA Gastrointestinal Markers 027-GD16 Celiac Disease Food Allergy...
... D kit is an enzymeimmunoassay for the ... metabolites in serum or plasma. Calibrators, controls ... 25-OH D. The diluted samples are incubated ... a highly specific sheep 25-OH D antibody ...
Medicine Products: